Related Experiment Video

Updated: May 28, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Safety of bivalirudin in patients with coronary artery disease

Mohamed Abdel-Wahab1, Gert Richardt

  • 1Herzzentrum, Segeberger Kliniken GmbH, Am Kurpark 1, 23795 Bad Segeberg, Germany. mohamed.abdel-wahab@segebergerkliniken.de

Expert Opinion on Drug Safety
|October 18, 2011
PubMed

Insights

Bivalirudin demonstrates a favorable safety profile for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI). It is recommended as a preferred antithrombotic agent, especially for ST-elevation myocardial infarction patients, alongside antiplatelet therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Unfractionated heparin (UFH) has limitations for coronary artery disease (CAD) patients, driving the need for alternative antithrombotic therapies.
  • Bivalirudin, a direct thrombin inhibitor, offers pharmacological advantages over UFH and is guideline-endorsed for acute coronary syndromes during percutaneous coronary intervention (PCI).
  • Assessing both ischemic and bleeding risks is crucial for optimizing antithrombotic strategies in CAD management.

Purpose of the Study:

  • To review the safety and tolerability of bivalirudin in CAD patients within approved indications.
  • To synthesize evidence from clinical trials, systematic reviews, meta-analyses, and registries (1992-2011).
  • To provide an overview of bivalirudin's pharmacology, efficacy, and safety in CAD.

Main Methods:

  • Literature review synthesizing evidence from 1992-2011.
  • Focus on clinical trials, systematic reviews, meta-analyses, and registries.
  • Evaluation of bivalirudin's safety and tolerability in CAD patients undergoing PCI.

Main Results:

  • Bivalirudin exhibits an impressive safety profile in CAD patients undergoing PCI.
  • It is a suitable alternative for patients with heparin-induced thrombocytopenia.
  • Bivalirudin is effective in ST-elevation myocardial infarction patients undergoing primary PCI.

Conclusions:

  • Bivalirudin is a safe and effective antithrombotic agent for CAD patients, particularly those undergoing PCI.
  • It is the recommended choice for patients with heparin-induced thrombocytopenia.
  • Bivalirudin should be the preferred agent for primary PCI in ST-elevation myocardial infarction, combined with early antiplatelet therapy.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...